Evaluating Ozanimod versus Fingolimod for Children with Relapsing Remitting Multiple Sclerosis
Official title: A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Run by Bristol-Myers Squibb · NCT06408259 · Data updated 2026-11-12
This study is testing whether ozanimod works better than fingolimod for children and teens with relapsing remitting multiple sclerosis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 10 Years to 17 Years |
| Sex | All |
| Enrollment | 194 (estimated) |
| Sponsor | Bristol-Myers Squibb Industry-sponsored |
| Locations | 33 sites (Loma Linda, California and 32 other locations) |
| Status | Recruiting |
| Started | April 8, 2025 |
| Main results expected | April 11, 2031 |
| Study ends | July 13, 2036 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT06408259 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children and adolescents diagnosed with relapsing remitting multiple sclerosis who have experienced recent disease activity.
✕Probably not a fit
Patients with progressive forms of multiple sclerosis or other significant immune system diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the effectiveness and safety of ozanimod compared to fingolimod in treating children and adolescents diagnosed with relapsing remitting multiple sclerosis (RRMS). Participants will receive either ozanimod, fingolimod, or a placebo, and the study will monitor drug levels, effects, and tolerability. The research focuses on individuals who have experienced recent disease activity, ensuring a targeted approach to treatment evaluation.
Why it matters
Potential benefit: If successful, this study could provide a new effective treatment option for children and adolescents with relapsing remitting multiple sclerosis.
How similar studies have gone: Previous studies have shown promise in evaluating treatments for multiple sclerosis, but this specific comparison of ozanimod and fingolimod in a pediatric population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease. * Meets at least 1 of the following criteria for disease activity: i) At least 1 MS relapse/attack in the previous year prior to screening. ii) At least 2 MS relapses/attacks in the previous 2 years prior to screening. iii) Evidence of 1 or more gadolinium-enhancing (GdE) lesions on magnetic resonance imaging (MRI) within 6 months prior to baseline (including screening MRI). \- Has an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, both inclusive. Exclusion Criteria: * Diagnosis of progressive forms of MS. * Active or chronic disease of the immune system other than MS. * Clinically relevant cardiovascular, hepatic, neurological other major systematic disease. * Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's running
-
University of California Davis Health
Sacramento, California, United States Recruiting -
University of South Florida
Tampa, Florida, United States Recruiting -
University of Chicago Medical Center
Chicago, Illinois, United States Recruiting -
University of Louisville, Norton Children's Research Institute
Louisville, Kentucky, United States Recruiting -
Medical College of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
Royal Children's Hospital
Melbourne, Victoria, Australia Recruiting
Show 27 more locations
-
University of Naples Federico II
Naples, Campania, Italy Recruiting -
Ospedale San Raffaele
Milan, Lombardy, Italy Recruiting -
Neurological Center Of Latium
Rome, Roma, Italy Recruiting -
2Ca Braga
Braga, Portugal Recruiting -
Unidade Local de Saúde de Coimbra, E.P.E.
Coimbra, Portugal Recruiting -
Centro Hospitalar de Lisboa Central
Lisbon, Portugal Recruiting -
Spitalul Clinic de Copii Doctor Victor Gomoiu
Bucharest, Bucharest, Romania Recruiting -
Prof. Dr. Alexandru Obregia Psychiatry Hospital
Bucharest, Bucharest, Romania Recruiting -
CHUVI- Hospital Alvaro Cunqueiro
Vigo, Pontevedra [Pontevedra], Spain Recruiting -
Hospital Universitario Virgen Macarena
Seville, Spain Recruiting -
Hospital Universitari i Politecnic La Fe
Valencia, Spain Recruiting -
Hospital Universitario Miguel Servet
Zaragoza, Spain Recruiting -
National Taiwan University Hospital
Taipei, Taiwan Recruiting -
Ondokuz Mayıs Universitesi
Samsun, Turkey (Türkiye) Recruiting -
Local Institution - 0114
Loma Linda, California, United States Not yet recruiting -
Local Institution - 0093
Chicago, Illinois, United States Withdrawn -
Local Institution - 0131
New Brunswick, New Jersey, United States Not yet recruiting -
Local Institution - 0132
Teaneck, New Jersey, United States Withdrawn -
Local Institution - 0091
Cincinnati, Ohio, United States Withdrawn -
Local Institution - 0092
Portland, Oregon, United States Not yet recruiting -
Local Institution - 0133
El Paso, Texas, United States Not yet recruiting -
Local Institution - 0081
Milan, Lombardy, Italy Not yet recruiting -
Local Institution - 0078
Mexico City, Dif, Mexico Withdrawn -
Local Institution - 0108
Poznan, Greater Poland Voivodeship, Poland Completed -
Local Institution - 0102
Porto, Portugal Withdrawn -
Local Institution - 0134
Caguas, Puerto Rico Not yet recruiting -
Local Institution - 0096
Esplugues de Llobregat, Barcelona [Barcelona], Spain Not yet recruiting
Study contacts
- Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Email: Clinical.Trials@bms.com
- Phone: 855-907-3286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Slip-and-trip motor training to reduce falls in relapsing‑remitting multiple sclerosis
This program tests whether repeated practice with controlled slips and trips helps ambulatory adults with relapsing‑remitting multiple sclerosis learn to react better and lower their chance of falling.
-
Effects of Ketogenic Diet on Multiple Sclerosis
This study is testing whether a ketogenic diet or a Mediterranean diet can help people with relapsing-remitting multiple sclerosis feel better and manage their symptoms.
-
Using magnetic stimulation to reduce fatigue in multiple sclerosis
This study is testing if a type of magnetic stimulation can help reduce fatigue in people with Relapsing-Remitting Multiple Sclerosis.
-
Treatment for Multiple Sclerosis Using Stem Cell Transplantation
This study is testing the long-term effects of a stem cell treatment for people with active relapsing-remitting multiple sclerosis to see how it impacts their health over five years.
-
Observational study of patients with Multiple Sclerosis in Switzerland
This study is trying to find out more about the early signs of Multiple Sclerosis and how it changes over time by looking at health data from patients in Switzerland.
-
Brief low-oxygen breathing to boost nerve plasticity and arm strength in MS
This will see if brief bouts of low-oxygen breathing (acute intermittent hypoxia) can quickly improve arm and hand strength and nerve signaling in people with relapsing-remitting MS who have arm weakness.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.